http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2019057445-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_35dbc60da9891d57c4047fb7b8689516 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-726 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K51-0482 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K51-1234 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-2207 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57484 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-595 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K51-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K51-088 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K51-1244 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K51-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-595 |
| filingDate | 2018-08-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5deead4c8a935970e0588b21d02f6f9f |
| publicationDate | 2019-03-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2019057445-A1 |
| titleOfInvention | MINIGASTRINE DERIVATIVES IN PARTICULAR FOR USE IN THE DIAGNOSIS AND / OR TREATMENT OF POSITIVE TUMORS FOR THE CCK2 RECEPTOR |
| abstract | The present invention relates to minigastrin derivatives which further enhance accumulation in CCK-2 receptor-positive tumors with simultaneous very low accumulation in other organs, for example the kidneys. The present invention relates to a minigastrin derivative of the formula: XZ-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH 2 (Y), wherein at least one of the linking or terminating amide linkages before or after the amino acids of the sequence Z, Ala, Tyr, Gly, Trp, Met, Asp, Phe and NH 2 or Y (C-terminal) is replaced by a 1,4-1,2,3-triazole disubstituted or 1,5-disubstituted, while X represents a chemical group attached to the peptide for diagnostic and / or therapeutic intervention on CCK-2 receptor related diseases, Y represents C-terminal modifications of the peptide , such as an amide, primary and secondary amides, free carboxylic acids and carboxylic ester derivatives including, but not limited to, amides and esters derived from alkyl, alkenyl, alkynyl, aromatic and linear or branched heterocyclic and Z represents a linker or DGlu *, DGlu * representing a D chain Glu comprising 1 to 6 repeats (-DGlu- to -DGlu-DGlu-DGlu-DGlu-DGlu-DGlu-). These minigastrin derivatives have high specific internalisation, excellent IC 50 values, and sufficient plasma stability. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2021186060-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3868394-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2021165285-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022023541-A1 |
| priorityDate | 2017-09-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 171.